McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments 
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
Apple Turns 50: From Garage Startup to AI Crossroads 
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
PHOENIX, July 17, 2017 -- Insys Therapeutics, Inc. (NASDAQ:INSY) (“Insys” or “the Company”) issued a statement today on its interactions with payors:
Insys, in concert with its business partners, is dedicated to helping patients navigate the complex payor environment that exists for patients as they seek to access the Insys products that their practicing health care providers have deemed appropriate or necessary for their treatment. As part of this endeavor, Insys is committed to establishing long-term partnerships in the healthcare community with public and private payors and operating with integrity and ethical standards that cultivate a culture of trust and transparency.
We believe that in the spirit of accountability, we have taken, and will continue to take, appropriate steps to learn from the past and to ensure that appropriate protocols and policies are in place at our Company. Where appropriate, Insys will vigorously advocate for fair patient access to medications, as well as vigorously defend itself within the legal and regulatory proceedings available to the Company.
About INSYS
Insys Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve the quality of life of patients. Using proprietary sublingual spray technology and capabilities to develop pharmaceutical cannabinoids, INSYS is developing a pipeline of products intending to address unmet medical needs and the clinical shortcomings of existing commercial products. INSYS currently markets one product, SUBSYS® (fentanyl sublingual spray) and has received approval for the marketing of SYNDROS™ (dronabinol oral solution), a proprietary, orally administered liquid formulation of dronabinol. INSYS is committed to developing medications for potentially treating addiction to opioids, opioid overdose, epilepsy, and other disease areas with a significant unmet need.
SUBSYS® and SYNDROS™ are trademarks of Insys Development Company, Inc., a subsidiary of Insys Therapeutics, Inc.
NOTE: All trademarks and registered trademarks are the property of their respective owners.
Investor Contact: Lisa M. Wilson 212-452-2793 E: [email protected]
